Acute Myocarditis after Pfizer-BioNTech COVID-19 m-RNA Vaccination

Main Article Content

Elena Grueva-Nastevska
Valentina Andova
Planinka Zafirovska
Ema Kandic
Ana Chelikikj
Elif Vrajnko
Simona Jovchevska
Oliver Busljetikj
Zhan Zimbakov
Igor M. Spiroski
Silvana Jovanova

Abstract

BACKGROUND: Prosthetic mechanical valve endocarditis (PVE) can be manifested as early PVE (acquired perioperatively) and late PVE (resulting from infections unrelated to the valve operation). Causes of both are similar but are late PVE are more prone to less virulent microbes. PVE resulting with paravalvular abscess is confirmed through echocardiography (transthoracic or transesophageal), it results with a high mortality rate especially if it is not early recognized.


CASE PRESENTATION: We are presenting a patient with heart failure symptoms caused by PVE after Pfizer-BioNTech coronavirus disease-2019 (COVID-19) m-RNA vaccination.


CONCLUSION: The exact mechanism of myocarditis in young men who received the second dose of mRNA COVID-19 vaccine is not yet known. However, this is a rare complication and most people generally recover quickly requiring only supportive treatment. In contrast, the risk of developing myocarditis from the viral infection is much higher.

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Grueva-Nastevska E, Andova V, Zafirovska P, Kandic E, Chelikikj A, Vrajnko E, Jovchevska S, Busljetikj O, Zimbakov Z, Spiroski IM, Jovanova S. Acute Myocarditis after Pfizer-BioNTech COVID-19 m-RNA Vaccination. SEE J Cardiol [Internet]. 2022 Nov. 30 [cited 2024 Mar. 2];3(1):11-4. Available from: https://seejca.eu/index.php/seejca/article/view/6032
Section
General Cardiology

References

Kunal S, Gupta K, Sharma SM, Pathak V, Mittal S, Tarke C. Cardiovascular system and COVID-19: Perspectives from a developing country. Monaldi Arch Chest Dis. 2020;90: 231-241. https://doi.org/10.4081/monaldi.2020.1305 PMid:32380802 DOI: https://doi.org/10.4081/monaldi.2020.1305

COVID-19 Subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS): Updated Guidance Regarding Myocarditis and Pericarditis Reported with COVID-19 mRNA Vaccines 9 July 2021 Statement [Last accessed on 2023 May 11].

Available from: https://www.cdc.gov/vaccines/covid-19/clinical- considerations/myocarditis.html [Last accessed on 2023 May 11].

Dilber E, Karagoz T, Aytemir K, Ozer S, Alehan D, Oto A, et al. Acute myocarditis associated with tetanus vaccination. Mayo Clin Proc. 2003;78(11):1431-3. https://doi.org/10.4065/78.11.1431-a PMid:14601707 DOI: https://doi.org/10.4065/78.11.1431-a

Saurina G, Shirazi S, Lane JM, Daniel B, DiEugenia L. Myocarditis after smallpox vaccination: A case report. Clin Infect Dis. 2003;37(1):145-6. https://doi.org/10.1086/377178 PMid:12830420 DOI: https://doi.org/10.1086/377178

Pfizer-BioNTech. COVID-19 Vaccine (BNT162, PF-07302048) FDA VRBPAC FDA; 2020. Available from: https://www.fda.gov/media/144246/download [Last accessed on 2020 Dec 10].

Helle EP, Koskenvuo K, Heikkila J, Pikkarainen J, Weckstrom P. Myocardial complications of immunisations. Ann Clin Res. 1978;10:280-7. PMid:736507

Cheng MP, Kozoris MG, Ahmadi AA, Kelsall J, Paquette K, Onrot JM. Post-vaccination myositis and myocarditis in a previously healthy male. Allergy Asthma Clin Immunol. 2016;12:6. https://doi.org/10.1186/s13223-016-0114-4 PMid:26877725 DOI: https://doi.org/10.1186/s13223-016-0114-4

Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: Expert recommendations. J Am Coll Cardiol. 2018;72(24):3158-76. https://doi.org/10.1016/j.jacc.2018.09.072 PMid:30545455 DOI: https://doi.org/10.1016/j.jacc.2018.09.072

Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, et al. 2015 ESC guidelines for the diagnosis and management of pericardial diseases: The task force for the diagnosis and management of pericardial diseases of the European society of cardiology (ESC) endorsed by: The European association for cardio-thoracic surgery (EACTS). Eur Heart J. 2015;36(42):2921-64. https://doi.org/10.1093/eurheartj/ehv318 PMid:26320112 DOI: https://doi.org/10.1093/eurheartj/ehv318

Garcia JB, Ortega PP, Fernandez JA, Leon AC, Burgos LR, Dorta EC. Acute myocarditis after administration of the BNT162b2 vaccine against COVID-19. Rev Esp Cardiol (Engl Ed). 2021;74(9):812-4. https://doi.org/10.1016/j.rec.2021.04.005 PMid:33994339 DOI: https://doi.org/10.1016/j.rec.2021.04.005

Marshall M, Ferguson ID, Lewis P, Jaggi P, Gagliardo C, Collins JS, et al. Symptomatic acute myocarditis in 7 adolescents following Pfizer-BioNTech COVID-19 vaccination. Pediatrics. 2021;148(3):e2021052478. https://doi.org/10.1542/peds.2021-052478 PMid:34088762 DOI: https://doi.org/10.1542/peds.2021-052478

Ammirati E, Cavalotti C, Milazzo A, Pedrotti P, Soriano F, Schroeder JW, et al. Temporal relation between second dose BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection. Int J Cardiol Heart Vasc. 2021;34:100774. https://doi.org/10.1016/j.ijcha.2021.100774 PMid:33821210 DOI: https://doi.org/10.1016/j.ijcha.2021.100774

Gargano JW, Wallace M, Hadler SC, Langley G, Su JR, Oster ME, et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: Update from the advisory committee on immunization practices-United States, June 2021. MMWR Morb Mortal Wkly Rep. 2021;70(27):977-82. https://doi.org/10.15585/mmwr.mm7027e2 PMid:34237049 DOI: https://doi.org/10.15585/mmwr.mm7027e2

Centers for Disease Control and Prevention Clinical considerations: Myocarditis and Pericarditis after Receipt of mRNA COVID-19 Vaccines among Adolescents and Young Adults; 2021. Available from: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html [Last accessed on 2023 May 11].

Most read articles by the same author(s)